Taysha Gene Therapies’ (TSHA) Overweight Rating Reaffirmed at Cantor Fitzgerald

Cantor Fitzgerald reiterated their overweight rating on shares of Taysha Gene Therapies (NASDAQ:TSHA) in a research report released on Tuesday,Benzinga reports. They currently have a $7.00 price target on the stock.

A number of other research firms have also weighed in on TSHA. Needham & Company LLC reaffirmed a “buy” rating and issued a $6.00 price objective on shares of Taysha Gene Therapies in a research note on Tuesday. Chardan Capital reaffirmed a “buy” rating and issued a $7.00 price target on shares of Taysha Gene Therapies in a research report on Tuesday, August 13th. Finally, Canaccord Genuity Group decreased their price objective on Taysha Gene Therapies from $7.00 to $6.00 and set a “buy” rating for the company in a report on Wednesday, August 14th. Eight investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus price target of $6.38.

Taysha Gene Therapies Price Performance

TSHA stock opened at $2.27 on Tuesday. Taysha Gene Therapies has a 1 year low of $1.19 and a 1 year high of $4.32. The stock has a market capitalization of $465.22 million, a PE ratio of 3.60 and a beta of 0.44. The company’s 50-day moving average is $1.98 and its 200-day moving average is $2.39. The company has a debt-to-equity ratio of 0.35, a current ratio of 5.22 and a quick ratio of 5.22.

Taysha Gene Therapies (NASDAQ:TSHA) last announced its quarterly earnings data on Monday, August 12th. The company reported ($0.09) EPS for the quarter, beating analysts’ consensus estimates of ($0.10) by $0.01. Taysha Gene Therapies had a negative return on equity of 168.91% and a negative net margin of 888.18%. The firm had revenue of $1.11 million during the quarter, compared to analysts’ expectations of $3.62 million. During the same quarter last year, the firm posted ($0.38) earnings per share. Equities research analysts expect that Taysha Gene Therapies will post -0.35 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in TSHA. Bank of New York Mellon Corp purchased a new stake in Taysha Gene Therapies in the second quarter worth $1,018,000. Creative Planning bought a new position in shares of Taysha Gene Therapies in the third quarter worth $28,000. SG Americas Securities LLC purchased a new stake in shares of Taysha Gene Therapies in the third quarter worth $129,000. Rhumbline Advisers bought a new stake in Taysha Gene Therapies during the second quarter valued at $413,000. Finally, Scientech Research LLC purchased a new position in Taysha Gene Therapies during the second quarter worth about $97,000. 77.70% of the stock is currently owned by hedge funds and other institutional investors.

Taysha Gene Therapies Company Profile

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.